BCSC
Breast Cancer Surveillance Consortium: Working together to advance breast cancer research
 
Home   |   Data   |   Statistics   |   Tools   |   Collaborations   |   Work with Us   |   Publications   |   About   |   Links

Benchmarks for Cancers by Indication for Examination for 363,048 Diagnostic Mammography Examinations from 2004 - 2008 -- based on BCSC data through 2009*

You are viewing the 2009 collection of this data. Data from other times are also available:
  Work-Up of Abnormal Screening Examination Short-Interval Follow-Up Evaluation of Breast Problem/ No Lump or Lump Unknown Evaluation of Breast Problem/ Palpable Lump All Diagnostic Examinations
Sensitivity** 88.3 60.2 77.6 89.1 83.9
Readers with 5+ cancers 210 77 112 158 290
True Positives 4,268 411 1,617 2,258 9,299
Cancers 4,833 683 2,084 2,533 11,087
Sensitivity (Median-50th percentile) 89.7 62.5 83.6 90.3 85.7
Sensitivity (25th, 75th percentiles) 81.3, 100 46.7, 71.4 72.4, 94.2 83.3, 100 77.8, 91.7
Sensitivity (10th, 90th percentiles) 71.1, 100 40, 83.3 59.0, 100 72.2, 100 66.0, 100
Specificity 87.8 96.2 94.3 87.2 91.4
Readers with 100+ non-cancers 224 164 148 106 311
True Negatives|| 98,686 57,511 82,254 28,696 288,916
Non-cancers# 112,431 59,810 87,187 32,902 316,006
Specificity (Median-50th percentile) 89.8 97 94.8 89.9 93
Specificity (25th, 75th percentiles) 85, 93.4 94.9, 98.3 91.9, 96.8 86.9, 93.4 89, 95.4
Specificity (10th, 90th percentiles) 78.7, 95.9 92.8, 99 89.4, 98.2 80.4, 96 85.8, 96.7

Notes

Numbers are frequencies unless otherwise indicated.

The first non-zero assessment within 90 days was used as the final assessment for analysis.

* Includes examinations for radiologists with minimum numbers of cases in a given column as designated; excludes examinations for which the radiologist is unknown.

** Sensitivity = the percentage of cancers that had an abnormal final interpretation (BI-RADS category 4 or 5; Note: 0 or 3 with a recommendation for biopsy was recoded as 4).

True Positive = the number of cancers that had an abnormal final interpretation (BI-RADS category 4 or 5; Note: 0 or 3 with a recommendation for biopsy was recoded as 4).

Cancers = the number of examinations with a tissue diagnosis of cancer within 1 year following the examination.

§ Specificity = the percentage of non-cancers that had a negative final interpretation (BI-RADS category 1, 2, or 3; Note: 0 with no recommendation for biopsy nor additional imaging/workup was recoded as 3, while 3 with a recommendation for biopsy was recoded as 4).

|| True Negative = the number of non-cancers that had a negative final interpretation (BI-RADS category 1, 2, or 3; Note: 0 with no recommendation for biopsy nor additional imaging/workup was recoded as 3, while 3 with a recommendation for biopsy was recoded as 4).

# Non-cancers = the number of examinations without a tissue diagnosis of cancer within 1 year following the examination.

Table numbers last updated Sept 30, 2013. The following source must be cited when reproducing this table: NCI-funded Breast Cancer Surveillance Consortium (HHSN261201100031C). Downloaded xx/xx/xxxx from the Breast Cancer Surveillance Consortium Web site - http://breastscreening.cancer.gov/statistics/benchmarks/diagnostic/2009/table7.html

[Return to Performance Benchmarks for Diagnostic Mammography]